TScan Therapeutics Announces Extra Share Purchase, Drives Up Stock Value
TScan Therapeutics Inc.sees a boost in share value after the announcement that the underwriters of its recent public offering have exercised their option to purchase additional shares.The company, which focuses on developing T cell receptor-engineered T cell therapies for cancer treatment, sold a total of 4,958,068 shares in the offering, resulting in approximately $167.8 million in gross proceeds.
With 94.829844 million shares outstanding and a current price of $7.26 per share, investors are taking notice of the positive impact of the additional share purchase on the company’s stock value.This news demonstrates confidence in TScan Therapeutics’ growth potential and ongoing commitment to developing innovative cancer treatments.
Comments